Aim: The aim of the study is the detection of primary and metastatic neuroendocrine tumors using super(111)In pentetreotide (OctreoScan), which is a long-acting analog of somatostatin. Patients and Methods: A total of 30 patients was investigated. Scintigraphy of the whole body, (and tomography 360 degree /6 degree if necessary) was performed 4h - 48 h after i.v. administration of 111MBq super(111)In pentetreotide. Results: In the group with 12 neuroendocrine carcinomas of unknown origin, there were 10 true positive (TP) findings (6 with liver metastases, one with liver, lung, and bone metastases, one with liver and mediastinal lymph node metastases and 2 with liver and retroperitoneal lymph node metastases), while 2 were false negative (FN) (poorly differentiated carcinoma with retroperitoneal metastases). In 6 patients scintigraphy influenced further patient management. From the group of 12 pancreatic neuroendocrine tumors, in 8 neuroendocrine pancreatic carcinomas, there were 6 TP (4 with liver metastases) and 2 FN (poorly differentiated). In 2 patients with pancreatic gastrinomas findings were TP, while in 2 patients with insulinoma one was TP and in the other TN. In 6 patients scintigraphy influenced further patient management while in 4 only contributed. From the group of 6 neuroendocrine lung tumors there were 4 TP (4 patients with bronchial carcinoid, two with liver metastases and the other two with liver, lung and bone metastases), in 1 patient with atypical lung carcinoid after surgery, findings were TN, while in one with neuroendocrine lung tumor (ACTH secreting) it was FN (small mediastinal tumor. In 2 patients scintigraphy influenced further patient management while in 2 only contributed. Because of the high uptake of radiopharmaceutical, and widespread metastases, six patients were indicated for radionuclide therapy with super(90)Y-DOTA TATE, and three of them received it. Conclusion: Preliminary results show that scintigraphy of neuroendocrine tumors is a useful method in diagnosis, staging and follow up of the patients suspected to have neuroendocrine tumors in the lungs. It is also helpful in the appropriate choice of therapy, including radionuclides.